A revolutionary method of editing the human genome has this week become the subject of a patent war. Back in April of 2014, patents were awarded by the USPTO (United States Patent and Trademark Office) to the Broad Institutes’ Dr. Feng Zhang, MIT, and Harvard to develop the technology behind "CRISPR-Cas9". This April, the UC Board of Regents’ legal team spoke with the USPTO about reconsidering their action, suggesting they award the patent to the inventor of the original method, UC Berkeley’s Jennifer Doudna. One way or another, this radical DNA modifier must be made.
We need X-Men, after all.